Citations

Clear

6273 citation(s) found for "To, Andrew".

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Eads, Jennifer R. , Hálfdánarson, Þorvarður R. , Asmis, Tim, Belizzi, Andrew M, Bergsland, Emily K. , Dasari, Arvind , El‐Haddad, Ghassan , Mittra, Erik , Myrehaug, Sten , Nakakura, Eric K. , Raj, Nitya , Untch, Brian R. , Vijayvergia, Namrata , Chan, Jennifer A. , Myrehaug, Sten , Soares, Heloisa P , Untch, Brian , Halfdanarson, Thorvardur R , Dasari, Arvind N , Frumovitz, Michael , Meyer, Joshua E. , Soares, Heloisa P.

Mayo Clinic

Endocrine-Related Cancer | May 15, 2023 | Volume: 30 | Issue: 8 | Pages: No page available

10.1530/erc-22-0206 | PMID 37184955 Get It

High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
Outpatient Antibiotic Use is Not Associated with an Increased Risk of First-Time Symptomatic Kidney Stones
Thongprayoon, Charat , Vaughan, Lisa E. , Frazee, Erin N. , Mehta, Ramila A. , Koo, Kevin , Schulte, Phillip J. , Lieske, John C. , Rule, Andrew D. , Rule, Andrew D , Lieske, John C , Thongprayoon, Charat

Mayo Clinic

Journal of the American Society of Nephrology | May 15, 2023 | Volume: 34 | Issue: 8 | Pages: 1399-1408

10.1681/asn.0000000000000155 | PMID 37184480 Get It

Significance Statement Antibiotics modify human microbiomes and may contribute to kidney stone risk. In a population-based case-control study using 1247 chart-validated first-time symptomatic kidney stone formers and 4024 age- and sex-matched controls, the risk of kidney stones was transiently higher during the first year after antibiotic use. However, this risk was no longer evident after adjustment for comorbidities and excluding participants with prior urinary symptoms. Findings were consistent across antibiotic classes and the number of antibiotic courses received. This suggests that antibiotics are not important risk factors of kidney stones. Rather, kidney stones when they initially cause urinary symptoms are under-recognized, resulting in antibiotic use before a formal diagnosis of kidney stones ( i.e. , reverse causality). Background Antibiotics modify gastrointestinal and urinary microbiomes, which may contribute to kidney stone formation. This study examined whether an increased risk of a first-time symptomatic kidney stone episode follows antibiotic use. Methods A population-based case-control study surveyed 1247 chart-validated first-time symptomatic kidney stone formers with a documented obstructing or passed stone (cases) in Olmsted County, Minnesota, from 2008 to 2013 and 4024 age- and sex-matched controls. All prescriptions for outpatient oral antibiotic use within 5 years before the onset of symptomatic stone for the cases and their matched controls were identified. Conditional logistic regression estimated the odds ratio (OR) of a first-time symptomatic kidney stone across time after antibiotic use. Analyses were also performed after excluding cases and controls with prior urinary tract infection or hematuria because urinary symptoms resulting in antibiotic prescription could have been warranted because of undiagnosed kidney stones. Results The risk of a symptomatic kidney stone was only increased during the 1-year period after antibiotic use (unadjusted OR, 1.31; P = 0.001), and this risk was attenuated after adjustment for comorbidities (OR, 1.16; P = 0.08). After excluding cases and controls with prior urinary symptoms, there was no increased risk of a symptomatic kidney stone during the 1-year period after antibiotic use (unadjusted OR, 1.04; P = 0.70). Findings were consistent across antibiotic classes and the number of antibiotic courses received. Conclusions The increased risk of a first-time symptomatic kidney stone with antibiotic use seems largely due to both comorbidities and prescription of antibiotics for urinary symptoms. Under-recognition of kidney stones that initially cause urinary symptoms resulting in antibiotic use may explain much of the perceived stone risk with antibiotics ( i.e. , reverse causality).
Letter on: 3D figure of epilepsy syndromes
Nordli, Douglas R. , Kim, Se Hee , Korff, Christian , Taha, Mohamed , Kim, Andrew, Phitsanuwong, Chalongchai , Nordli, Douglas R., Nordli Iii, Douglas R , Nordli, Douglas R.

Mayo Clinic

Epilepsia Open | May 15, 2023 | Volume: 8 | Issue: 3 | Pages: 1202-1204

10.1002/epi4.12762 | PMID 37183581 Get It

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac, Adam , Landsburg, Daniel J. , Hughes, Mitchell E. , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie , Stepanovic, Adam , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Farooq, Umar , Saad, Mahak, Evens, Andrew M. , Pandya, Karan, Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Oh, Timothy S. , Nutsch, Heather, Rubinstein, P , Chaudhry, Amina, Zayac, Adam S , Medeiros, L Jeffrey , Kurt, Habibe , Torka, Pallawi , Sundaram, Suchitra , Smith, Stephen D , Naresh, Kikkeri N , Karimi, Yasmin H , Epperla, Narendranath , Bond, David A , Farooq, Umar , Evens, Andrew M , Naik, Seema G , Kamdar, Manali , Haverkos, Bradley M , Karmali, Reem , Oh, Timothy S , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Landsburg, Daniel J , Hu, Marie , Li, Shaoying , Girton, Mark , Medeiros, L. Jeffrey , Kurt, Habibe , Epperla, Narendranath , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | May 12, 2023 | Volume: 7 | Issue: 21 | Pages: 6381-6394

10.1182/bloodadvances.2023009731 | PMID 37171397 Get It

Abstract In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.
Pre-hematopoietic stem cell transplantation lung computed tomography is not an alternative to PFT for pediatric patients with sickle cell disease
Ngwube, Alexander , Ritchey, Andrew , Mirea, Lucia , Williams, Sophia , Adams, Roberta H. , Mirea, Lucia , Adams, Roberta, Garcia, Angela

Mayo Clinic

Pediatric Hematology and Oncology | May 11, 2023 | Volume: 40 | Issue: 7 | Pages: 696-700

10.1080/08880018.2023.2186554 | PMID 37166203 Get It

Socioeconomic and Racial/Ethnic Disparities in Perception of Health Status and Literacy in Spine Oncological Patients
Elsamadicy, Aladine A. , Wang, Chelsea, Craft, Samuel , Rajjoub, Rami , Pennington, Zach , Lo, Sheng-Fu Larry , Mendel, Ehud , Sciubba, Daniel M. , Pennington, Zach , Reeves, Benjamin C. , Sherman, Josiah , Koo, Andrew B. , Hersh, Andrew M. , Shin, John H.

Mayo Clinic

Spine | May 10, 2023 | Volume: 48 | Issue: 15 | Pages: 1107-1115

10.1097/brs.0000000000004712 | PMID 37163649 Get It

Study Design. A cross-sectional study was performed using the National Institutes of Health All of Us survey database. Objective. The aim of this study was to assess socioeconomic and racial disparities in the perception of personal health, health literacy, and healthcare access among spine oncology patients. Summary of Background Data. Racial, ethnic, and socioeconomic disparities in health literacy and perception of health status have been described for many disease processes. However, few studies have assessed the prevalence of these disparities among spine oncology patients. Methods. Adult spine oncology patients, identified using ICD-9/10-CM codes, were categorized by race/ethnicity: White/Caucasian (WC), Black/African-American (BAA), and Non-White Hispanic (NWH). Demographics and socioeconomic status were assessed. Questionnaire responses regarding baseline health status, perception of health status, health literacy, and barriers to healthcare were compared. Results. Of the 1,175 patients identified, 207 (17.6%) were BAA, 267 (22.7%) were NWH, and 701 (59.7%) were WC. Socioeconomic status varied among cohorts, with WC patients reporting higher levels of education (P<0.001), annual income greater than $50K (P<0.001), and home ownership (P<0.001). BAA and NWH patients reported greater rates of 7-day “Severe fatigue” (P<0.001) and “10/10 pain” (P<0.001) and lower rates of “Completely” able to perform everyday activities (P<0.001). WC patients had a higher response rate for “Excellent/Very Good” regarding their own general health (P<0.001) and quality (P<0.001). The WC cohort had a significantly higher proportion of patients responding “Never” when assessing difficulty understanding (P<0.001) and needing assistance with health materials (P<0.001). BAA and NWH were significantly less likely to report feeling “Extremely” confident with medical forms (P<0.001). BAA and NWH had significantly higher response rates to feeling “Somewhat Worried” about healthcare costs (P<0.001) and with delaying medical care given “Can’t Afford Co-pay” (P<0.001). Conclusion. We identified disparities in perception of health status, literacy, and access among spine oncology patients. Level of Evidence. 4
Rotational atherectomy for calcified lesions during ST-segment elevation myocardial infarction: a case series and literature review
Brown, Kristen N. , Jhand, Aravdeep , Chatzizisis, Yiannis S. , Jhand, Aravdeep S, Goldsweig, Andrew M.

Mayo Clinic

European Heart Journal - Case Reports | May 10, 2023 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/ehjcr/ytad207 | PMID 37207108 Get It

Abstract Background ST elevation myocardial infarction (STEMI) has traditionally been a relative contraindication for the utilization of rotational atherectomy (RA). However, in severely calcified lesions, RA may be necessary to facilitate stent delivery. Case summary Three patients who present with STEMI are found to have severely calcified lesions on intravascular ultrasound. Equipment was unable to pass the lesions in all three cases. Rotational atherectomy was therefore performed to allow for stent passage. All three cases had achieved successful revascularization with no intraoperative or post-operative complications. The patients remained angina-free the rest of their hospitalization and at the 4 month follow-up. Discussion Rotational atherectomy for calcific plaque modification during STEMI when equipment will not pass is a feasible and safe therapeutic option.
Postoperative Transfusions after Administration of Delayed Cold-stored Platelets versus Room Temperature Platelets in Cardiac Surgery: A Retrospective Cohort Study
Zec, Simon , Hanson, Andrew C. , Weister, Tim, Stubbs, James R. , Kor, Daryl J. , Warner, Matthew A. , Klompas, Allan M. , Zec, Simon , Stubbs, James, Warner, Matthew A , Weister, Timothy J.

Mayo Clinic

Anesthesiology | May 8, 2023 | Volume: 139 | Issue: 2 | Pages: 153-163

10.1097/aln.0000000000004605 | PMID 37155364 Get It

Background Delayed cold storage of room temperature platelets may extend shelf life from 5 to 14 days. The study hypothesized that the use of delayed cold-stored platelets in cardiac surgery would be associated with decreased postoperative platelet count increments but similar transfusion and clinical outcomes compared to room temperature-stored platelets. Methods This is an observational cohort study of adults transfused with platelets intraoperatively during elective cardiac surgery between April 2020 and May 2021. Intraoperative platelets were either room temperature-stored or delayed cold-stored based on blood bank availability rather than clinical features or provider preference. Differences in transfusion and clinical outcomes, including a primary outcome of allogenic transfusion exposure in the first 24 h postoperatively, were compared between groups. Results A total of 713 patient encounters were included: 529 (74%) room temperature-stored platelets and 184 (26%) delayed cold-stored platelets. Median (interquartile range) intraoperative platelet volumes were 1 (1 to 2) units in both groups. Patients receiving delayed cold-stored platelets had higher odds of allogeneic transfusion in the first 24 h postoperatively (81 of 184 [44%] vs. 169 of 529 [32%]; adjusted odds ratio, 1.65; 95% CI, 1.13 to 2.39; P = 0.009), including both erythrocytes (65 of 184 [35%] vs. 135 of 529 [26%]; adjusted odds ratio, 1.54; 95% CI, 1.03 to 2.29; P = 0.035) and platelets (48 of 184 [26%] vs. 79 of 529 [15%]; adjusted odds ratio, 1.91; 95% CI, 1.22 to 2.99; P = 0.005). There was no difference in the number of units administered postoperatively among those transfused. Platelet counts were modestly lower in the delayed cold-stored platelet group (−9 × 109/l; 95% CI, −16 to −3]) through the first 3 days postoperatively. There were no significant differences in reoperation for bleeding, postoperative chest tube output, or clinical outcomes. Conclusions In adults undergoing cardiac surgery, delayed cold-stored platelets were associated with higher postoperative transfusion utilization and lower platelet counts compared to room temperature-stored platelets without differences in clinical outcomes. The use of delayed cold-stored platelets in this setting may offer a viable alternative when facing critical platelet inventories but is not recommended as a primary transfusion approach. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
International Epidemiology of Carbapenemase-Producing Escherichia coli
Boutzoukas, Angelique E , Komarow, Lauren , Chen, Liang , Hanson, Blake , Liu, Zhengyin , Mendoza, Soraya Salcedo, Ordóñez, Karen , Wang, Minggui , Ge, Lizhao , Giri, Abhigya, Hill, Carol , Baum, Keri, Kreiswirth, Barry N. , Patel, Robin , Arias, César A. , Chambers, Henry F. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Jean, Francois Jabbour, Fujie, Zhang, Judith, J Lok, Robert, A Salata, Martin, Stryjewski, Valentina, Di Castelnuovo, Jose, Millan Oñate Gutierrez, Eric, Cober, Susan, Richter, Deverick, J Anderson, Beth, Evans, Carol, Hill, Heather, Reich, Keri, Baum, Rebekka, Arias, Vance, G Fowler, Karen, Ordoñez, Jesse, T Jacob, Li, Linghua , Barry, Neil, Samit, Desai, Erica, Herc, Ezequiel, Cordova, Maria, R Ponisio, Samuel, Vichez, Marisa, Laëtitia , Sandra, Valderrama, Jairo, Figueroa, Cesar, A Arias, An, Qiang , Diane, Panesso, Kirsten, R., Truc, Thanh, Jiachun, Su, Jiang, Jianping , Ming-gui, Wang, Xu, Xiaogang , Yang, Yang , Jose, M Munita, Maria, Spencer, Thamer, Alenazi, Robert, Alain, Steven, Hersch, Susan, Davies, Charles, Huskins, Kerry, G, Robin, Patel, Suzannah, Schmidt-Malan, Sara, Revolinski, Glenn, Wortmann, Robert, C Kalayjian, Greg, Weston, Belinda, Ostrowsky, Gopi, Patel, Daniel, E Furst, Angela, Kim, Julia, Garcia-Diaz, Soraya, Salcedo, John, Jeffy, Zhengyin, Liu, Andrew, Henderson, David, Louis, Qing, Xie, Keith, S Kaye, Gao, Hainv , Yu, Yunsong , Mary, Waters, Bettina, C Fries, Brandon, Eilertson, Kean, Lee Chew, Nares, Smitasin, Paul, Ananth Tambyah, Jason, Christopher, Anton, Peleg, Marcel, L. Saint, Lan-juan, LI , Lauren, Komarow, Lizhao, Ge, Scott, Evans, Todd, McCarty, Henry, Fitjerald , Omai, B Garner, Lilian, M Abbo, David, van Duin, Ebbing, Lautenbach, Jennifer, Harrington, Yohei, Doi, Darren, W Logan, Blake, Hanson, Jinnethe, Reyes, Maria, Virginia Villegas Botero, Lorena, Diaz, Federico, P., Ritu, Banerjee, Sorabh, Dhar, Michael, Joy S, Zhiyong, Zong, Stryjewski, Martín E. , Villegas, María Virginia , Wang, Minggui , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Villegas, Maria Virginia , Kanj, Souha S. , Paterson, David L. , Evans, Scott , Bonomo, Robert A. , Kreiswirth, Barry N , Arias, César A. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Fujie, Zhang, Jose, Millan-Onate, Eric, Cober, Barry, N Kreiswirth, Claudia, Manca, Marisa, L Sanchez, An, Q Dinh, Kirsten, Rydell, Hu, Fupin , Maria, Spencer-Sandino, Robert, A Bonomo, Steven, H Marshall, Susan, D Rudin, Glenn, Wortmann, Gopi, Patel, Zhengyin, Liu, David, L Paterson, Qing, Xie, Marimuthu, Kalisvar , Anton, Peleg, Henry, F Chambers, Ebbing, Lautenbach, Jennifer, H Han, Lorena, Diaz, Federico, Perez, Ritu, Banerjee, Zhiyong, Zong

Mayo Clinic

Clinical Infectious Diseases | May 8, 2023 | Volume: 77 | Issue: 4 | Pages: 499-509

10.1093/cid/ciad288 | PMID 37154071 Get It

Abstract Background Carbapenemase-producing (CP) Escherichia coli (CP-Ec) are a global public health threat. We aimed to describe the clinical and molecular epidemiology and outcomes of patients from several countries with CP-Ec isolates obtained from a prospective cohort. Methods Patients with CP-Ec were enrolled from 26 hospitals in 6 countries. Clinical data were collected, and isolates underwent whole-genome sequencing. Clinical and molecular features and outcomes associated with isolates with or without metallo-β-lactamases (MBLs) were compared. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after the index culture. Results Of the 114 CP-Ec isolates in Consortium on resistance against carbapenems in Klebsiella and other Enterobacterales-2 (CRACKLE-2), 49 harbored an MBL, most commonly blaNDM-5 (38/49, 78%). Strong regional variations were noted with MBL-Ec predominantly found among patients in China (23/49). Clinically, MBL-Ec were more often from urine sources (49% vs 29%), less often met criteria for infection (39% vs 58%, P = .04), and had lower acuity of illness when compared with non–MBL-Ec. Among patients with infection, the probability of a better DOOR outcome for a randomly selected patient with MBL-Ec as compared with non–MBL-Ec was 62% (95% CI: 48.2–74.3%). Among infected patients, non–MBL-Ec had increased 30-day (26% vs 0%; P = .02) and 90-day (39% vs 0%; P = .001) mortality compared with MBL-Ec. Conclusions Emergence of CP-Ec was observed with important geographic variations. Bacterial characteristics, clinical presentations, and outcomes differed between MBL-Ec and non–MBL-Ec. Mortality was higher among non-MBL isolates, which were more frequently isolated from blood, but these findings may be confounded by regional variations.
Immune checkpoint inhibitor‐associated central nervous system autoimmunity
Valencia-Sánchez, Cristina , Pittock, Sean J. , Ζεκερίδου, Αναστασία , Pittock, S J , Flanagan, E P , Zekeridou, Anastasia , Valencia Sanchez, Cristina , Sechi, Elia , Dubey, Divyanshu , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

European Journal of Neurology | May 8, 2023 | Volume: 30 | Issue: 8 | Pages: 2418-2429

10.1111/ene.15835 | PMID 37151179 Get It

Abstract Background and purpose Outcome and rechallenge data on central nervous system (CNS) autoimmunity triggered by immune checkpoint inhibitors (ICIs) are limited. We aim to describe a large series of patients with ICI‐triggered CNS autoimmunity, and to compare these patients with spontaneous paraneoplastic syndromes (PNS). Methods We retrospectively reviewed Mayo Clinic patients with ICI‐triggered CNS autoimmunity (February 2015–June 2021). Clinical characteristics were compared to spontaneous PNS patients (with antineuronal nuclear antibody [ANNA]‐1 or anti‐Hu neurological autoimmunity, and/or neuroendocrine tumors [NET]) evaluated within the same period. Results Thirty‐one patients were included (55% female, median age = 63 years, range = 39–76). Median time from ICI initiation was 3.65 months (range = 0.8–44.5). The most common associated malignancies were melanoma and small cell lung cancer. CNS manifestations included encephalitis ( n = 16), meningoencephalitis ( n = 8), cerebellar ataxia ( n = 4), demyelinating syndrome ( n = 2), and myelopathy ( n = 1). Magnetic resonance imaging was abnormal in 62%. Cerebrospinal fluid was inflammatory in 70%. Neural autoantibodies were identified in 47%, more frequently in patients with NET ( p = 0.046). ICI was discontinued in 97%; 90% received immunosuppressive treatment. After median 6.8 months follow‐up (range = 0.7–46), 39% had unfavorable outcomes (grade ≥ 3). This was associated with higher severity degree at onset, shorter period from ICI to neurological symptom onset, and encephalitis. Four patients were rechallenged with ICI, and one relapsed. Patients with NET and with ANNA‐1 ICI‐triggered CNS autoimmunity had associated peripheral nervous system manifestations more frequently than their spontaneous counterparts ( p = 0.007 and p = 0.028, respectively). Conclusions One third of ICI‐related CNS autoimmunity patients have unfavorable outcomes. Relapses may occur after ICI rechallenge. Neural autoantibodies are often present, more commonly in patients with NET.